Success for Takeda in trial testing subcutaneous version of vedolizumab

19 July 2018

Japan’s Takeda Pharmaceutical (TTO: 4502) has unveiled positive top-line results from the VISIBLE 1 clinical trial looking into a new subcutaneous version of its top-selling anti-inflammatory vedolizumab, currently marketed in intravenous form as Entyvio.

The trial is investigating the new formulation as a maintenance therapy for adult patients with moderately to severely active ulcerative colitis (UC) who are responding well to Entyvio.

Takeda says the trial met its primary endpoint, with a statistically-significant proportion of patients receiving vedolizumab SC beginning at week 6 and every two weeks following achieving clinical remission at week 52, compared to placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK